The phase 2 CITYSCAPE clinical trial showed significant progression-free survival and ORR benefits for the first-line combination of tiragolumab (anti-TIGIT antibody) and atezolizumab, compared to atezolizumab monotherapy in PD-L1 positive metastatic NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.